140 related articles for article (PubMed ID: 37263806)
1. Development of New Donor-Specific and Human Leukocyte Antigen Antibodies After Transfusion in Adult Lung Transplantation.
Stoker A; Hicks A; Wright MC; Ali A; Klapper J; Poisson J; Zaffiri L; Chen D; Hartwig M; Ghadimi K; Welsby I; Bottiger B
J Cardiothorac Vasc Anesth; 2023 Sep; 37(9):1609-1617. PubMed ID: 37263806
[TBL] [Abstract][Full Text] [Related]
2. Association between blood transfusion after kidney transplantation and risk for the development of de novo HLA donor-specific antibodies and poor clinical outcomes: A single-center retrospective study.
Kang ZY; Liu C; Liu W; Li D
Transpl Immunol; 2023 Dec; 81():101930. PubMed ID: 37730183
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
[TBL] [Abstract][Full Text] [Related]
4. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies.
Cuevas E; Arreola-Guerra JM; Hernández-Méndez EA; Salcedo I; Castelán N; Uribe-Uribe NO; Vilatobá M; Contreras-Saldívar AG; Sánchez-Cedillo AI; Ramírez JB; de Rungs D; Granados J; Morales-Buenrostro LE; Alberú J
Nephrol Dial Transplant; 2016 Oct; 31(10):1738-45. PubMed ID: 27220757
[TBL] [Abstract][Full Text] [Related]
5. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT
Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
[TBL] [Abstract][Full Text] [Related]
6. Eplet Mismatch Load and
Senev A; Coemans M; Lerut E; Van Sandt V; Kerkhofs J; Daniëls L; Driessche MV; Compernolle V; Sprangers B; Van Loon E; Callemeyn J; Claas F; Tambur AR; Verbeke G; Kuypers D; Emonds MP; Naesens M
J Am Soc Nephrol; 2020 Sep; 31(9):2193-2204. PubMed ID: 32764139
[TBL] [Abstract][Full Text] [Related]
7. Early clearance vs persistence of de novo donor-specific antibodies following lung transplantation.
Islam AK; Sinha N; DeVos JM; Kaleekal TS; Jyothula SS; Teeter LD; Nguyen DTM; Eagar TN; Moore LW; Puppala M; Wong STC; Knight RJ; Frost AE; Graviss EA; Osama Gaber A
Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28658512
[TBL] [Abstract][Full Text] [Related]
8. De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation.
Safavi S; Robinson DR; Soresi S; Carby M; Smith JD
J Heart Lung Transplant; 2014 Dec; 33(12):1273-81. PubMed ID: 25130554
[TBL] [Abstract][Full Text] [Related]
9. Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction.
Iasella CJ; Ensor CR; Marrari M; Mangiola M; Xu Q; Nolley E; Moore CA; Morrell MR; Pilewski JM; Sanchez PG; McDyer JF; Zeevi A
J Heart Lung Transplant; 2020 Dec; 39(12):1417-1425. PubMed ID: 32981841
[TBL] [Abstract][Full Text] [Related]
10. Effect of blood transfusion post kidney transplantation on de novo human leukocytes antigen donor-specific antibody development and clinical outcomes in kidney transplant recipients: A systematic review and meta-analysis.
Kang ZY; Ma S; Liu W; Liu C
Transpl Immunol; 2023 Jun; 78():101801. PubMed ID: 36841513
[TBL] [Abstract][Full Text] [Related]
11. De-novo donor-specific anti-HLA antibodies 30 days after lung transplantation are associated with a worse outcome.
Le Pavec J; Suberbielle C; Lamrani L; Feuillet S; Savale L; Dorfmüller P; Stephan F; Mussot S; Mercier O; Fadel E
J Heart Lung Transplant; 2016 Sep; 35(9):1067-77. PubMed ID: 27373824
[TBL] [Abstract][Full Text] [Related]
12. Shared alloimmune responses against blood and transplant donors result in adverse clinical outcomes following blood transfusion post-renal transplantation.
Hassan S; Regan F; Brown C; Harmer A; Anderson N; Beckwith H; Roufosse CA; Santos-Nunez E; Brookes P; Taube D; Willicombe M
Am J Transplant; 2019 Jun; 19(6):1720-1729. PubMed ID: 30582278
[TBL] [Abstract][Full Text] [Related]
13. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome.
Palmer SM; Davis RD; Hadjiliadis D; Hertz MI; Howell DN; Ward FE; Savik K; Reinsmoen NL
Transplantation; 2002 Sep; 74(6):799-804. PubMed ID: 12364858
[TBL] [Abstract][Full Text] [Related]
14. Clinical Outcomes of Lung Transplantation in the Presence of Donor-Specific Antibodies.
Courtwright AM; Cao S; Wood I; Mallidi HR; Kawasawa J; Moniodis A; Ng J; El-Chemaly S; Goldberg HJ
Ann Am Thorac Soc; 2019 Sep; 16(9):1131-1137. PubMed ID: 31026404
[No Abstract] [Full Text] [Related]
15. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes.
Freitas MC; Rebellato LM; Ozawa M; Nguyen A; Sasaki N; Everly M; Briley KP; Haisch CE; Bolin P; Parker K; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
Transplantation; 2013 May; 95(9):1113-9. PubMed ID: 23514959
[TBL] [Abstract][Full Text] [Related]
16. Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation.
Lobo LJ; Aris RM; Schmitz J; Neuringer IP
J Heart Lung Transplant; 2013 Jan; 32(1):70-7. PubMed ID: 23260706
[TBL] [Abstract][Full Text] [Related]
17. The allograft injury marker CXCL9 determines prognosis of anti-HLA antibodies after lung transplantation.
Shino MY; Zhang Q; Li N; Derhovanessian A; Ramsey A; Saggar R; Britton IN; Amubieya OO; Lari SM; Hickey M; Reed EF; Noble PW; Stripp BR; Fishbein GA; Lynch JP; Ardehali A; Sayah DM; Weigt SS; Belperio JA
Am J Transplant; 2022 Feb; 22(2):565-573. PubMed ID: 34464505
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of pre-transplant anti-HLA antibodies and their impact on outcomes in lung transplant recipients.
Park JE; Kim CY; Park MS; Song JH; Kim YS; Lee JG; Paik HC; Kim SY
BMC Pulm Med; 2018 Mar; 18(1):45. PubMed ID: 29529999
[TBL] [Abstract][Full Text] [Related]
19. Poor graft outcome in recipients with de novo donor-specific anti-HLA antibodies after living related kidney transplantation.
Li X; Ishida H; Yamaguchi Y; Tanabe K
Transpl Int; 2008 Dec; 21(12):1145-52. PubMed ID: 18803618
[TBL] [Abstract][Full Text] [Related]
20. De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients.
Del Bello A; Congy-Jolivet N; Danjoux M; Muscari F; Lavayssière L; Esposito L; Cardeau-Desangles I; Guitard J; Dörr G; Milongo D; Suc B; Duffas JP; Alric L; Bureau C; Guilbeau-Frugier C; Rostaing L; Kamar N
Transpl Int; 2015 Dec; 28(12):1371-82. PubMed ID: 26303035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
